Kinetoplast-Directed Therapies: A Selective Mitochondrial Approach to Combat Leishmaniasis

Area of Science:

• Parasitology
• Drug Discovery
• Tropical Medicine

Background:

• Leishmaniases are neglected tropical diseases caused by *Leishmania* protozoa and transmitted by sandflies.
• Current treatments for leishmaniasis are suboptimal due to issues like drug resistance, cost, and availability.
• There is a critical need for novel, effective therapeutic strategies against leishmaniasis.

Purpose of the Study:

• To review recent advancements in rational drug design targeting the kinetoplast in *Leishmania* parasites.
• To explore innovative approaches for delivering anti-leishmanial agents to the parasite's mitochondria.
• To assess the translational relevance of the kinetoplast as a selective drug target.

Main Methods:

• Focus on rational drug design strategies.
• Discussion of mitochondrion-targeted small molecules.
• Exploration of ligand-functionalized nanoparticle delivery systems.

Main Results:

• The kinetoplast, a unique mitochondrial organelle, is a promising target for anti-leishmanial drug development.
• Targeting specific kinetoplast components like kDNA, G-quadruplexes, and topoisomerases shows potential.
• Mitochondrion-targeted agents and nanoparticle delivery systems enhance drug delivery to the parasite's mitochondria.

Conclusions:

• The kinetoplast's unique molecular machinery offers a highly selective target for developing new anti-leishmanial drugs.
• Mitochondrion-targeted therapies and advanced delivery systems represent a promising avenue for treating leishmaniasis.
• Careful evaluation of potential host cell mitochondrial liabilities is necessary for safe and effective drug development.